Targeting brain tumors with nanoparticles for treatment
Official title: Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)
Funded at Nanovalent Pharmaceuticals, INC. · NIH-11081824 · Data updated 2026-11-12
This study is testing a new kind of tiny particle that can deliver cancer-fighting drugs right to brain tumors, hoping to shrink the tumors and help people with glioblastoma live longer and healthier lives.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nanovalent Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Bozeman, United States) |
| Project start | August 8, 2023 |
| Project end | July 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,000,000 |
| NIH project number | 4R42CA281707-02 |
| Project ID | NIH-11081824 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who have been diagnosed with glioblastoma or other intractable brain tumors.
✕Less likely to help
Patients with brain tumors that are not glioblastoma or those who are not eligible for nanoparticle therapy may not benefit from this research.
What this research studies
This research focuses on developing a new type of nanoparticle that can cross the blood-brain barrier to deliver cancer-fighting drugs directly to glioblastoma cells. By using these targeted nanoparticles, the goal is to reduce tumor size and improve survival rates for patients with this aggressive brain cancer. The approach involves encapsulating cytotoxic drugs within the nanoparticles, which are designed to bind to tumor cells and release their therapeutic cargo once inside. This innovative method aims to overcome the limitations of traditional chemotherapy for brain tumors.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with glioblastoma, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promise in using nanoparticles for targeted drug delivery in cancer treatment, indicating potential success for this novel approach.
Where this research is happening
-
Nanovalent Pharmaceuticals, INC.
Bozeman, United States Active
Researchers
- Principal investigator: Nagy, Jon Owen — Nanovalent Pharmaceuticals, INC.
- Study coordinator: Nagy, Jon Owen
Related research
Other NIH-funded projects on the same topics.
-
Targeted Nanoparticles for Glioblastoma Brain Tumors
This project is developing tiny, targeted particles to deliver medicine directly to brain tumor cells, aiming to help people with glioblastoma.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.